Search Results

ARVN Arvinas, Inc. - Fundamental Analysis

BEARISH
Sign in to save Save this symbol to a watchlist or track a position.
ARVN Stock | Fundamental Analysis & Investment Insights
NASDAQ Healthcare Biotechnology
Current Price Live
$12.18
Analyst Target
$14.56
+19.6% Upside
52W High
$14.51
52W Low
$5.9

At a glance

Key valuation, profitability, growth, and risk metrics.

Unlock key metrics

Market cap, P/E, ROE, margins, leverage and more.

AI Analysis

Powered by advanced machine learning algorithms

Confidence Score
85%
Analysis Accuracy
ARVN's Advanced Deterministic Scorecard reveals severe financial distress: a Piotroski F-Score of 0/9 indicates extreme operational weakness, and the absence of an Altman Z-Score suggests no solvency validation. Despite a strong gross margin of 100.00%, the company reports a -30.77% profit margin, -754.74% operating margin, and an 84% YoY revenue decline, signaling fundamental business deterioration. Insider selling activity totaling $0.83M over six months, with multiple officer and CEO sales, reinforces bearish sentiment. While the stock has rebounded 42.5% over the past year, this is likely driven by speculative momentum rather than fundamentals, and the current price of $12.18 remains elevated relative to its deteriorating performance.

Key Strengths

Gross margin of 100.00% indicates potential product pricing power or low production costs
Extremely low debt/equity ratio of 0.02 suggests minimal financial leverage risk
High current and quick ratios (4.92 and 4.86) reflect strong short-term liquidity
Analyst consensus recommends 'buy' with a target price of $14.56, indicating some market optimism
Recent 6-month price surge of 57.4% suggests strong short-term momentum

Key Risks

Piotroski F-Score of 0/9 signals severe financial distress and operational failure
84% YoY revenue decline and negative operating margin (-754.74%) indicate business contraction and unsustainable operations
Insider selling of $0.83M in the last 6 months, including CEO and officer sales, signals loss of confidence
No positive profitability metrics: negative ROE (-16.23%), ROA (-7.94%), and negative forward P/E (-3.49)
No dividend, no free cash flow, and no intrinsic value or Graham Number available, indicating no defensive or value characteristics

Performance Snowflake

Multi-dimensional AI analysis across 5 key categories

Unlock AI-Powered Analysis

See Value, Future Performance, Past Performance, Financial Health & Dividend scores

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Unlock Price Charts

View historical price trends and analyst targets

Historical Performance Trends

Long-term financial metrics and growth patterns

Unlock Historical Data

View 3-year revenue, profit margins, and growth trends

Valuation Metrics

Key valuation ratios and pricing indicators

Sign up to view

P/E, P/B, P/S, EV/EBITDA and more

Profitability, Growth & Financial Health

Detailed profit margins, ROE, debt ratios, and liquidity metrics

Unlock Detailed Metrics

View ROE, Operating Margin, Debt/Equity, Current Ratio and more

Sector Comparison & Peer Analysis

Compare ARVN against industry averages and similar companies

Unlock Sector Insights

See how ARVN compares to competitors and industry standards

Insider Trading & Analyst Ratings

Track insider transactions and Wall Street analyst recommendations

Unlock Insider Data

See recent insider buys/sells and analyst price targets

Past News Coverage

Recent headlines mentioning ARVN from our newsroom.

Newest → oldest

See the full ARVN analysis

Free signup • Unlock all metrics • No credit card required

TradingGPT V1 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile